Compare SoundHound AI Inc (SOUN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? SoundHound AI Inc trades at $6.56 (market cap $2.75B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 44.3× SoundHound AI Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| SOUN | VRTX | |
|---|---|---|
Market Cap | $2.75B | $121.95B |
Sector | Technology | Health |
52-Week High | $21.40 | $529.59 |
52-Week Low | $5.90 | $366.54 |
Enterprise Value | $2.54B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $6.31, up 0.64% today, but remains down 37% year-to-date. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $168.92 million in 2025, but net losses widened to -$14.01 million. Recent news highlights its leadership in conversational AI, yet concerns over cash burn persist. Analyst consensus is bullish with a $13.00 price target, indicating significant potential upside from current levels.
Outlook: High growth potential in voice AI markets contrasts with persistent losses and negative cash flow. Investment opportunity lies in market expansion and acquisitions, but risks include execution challenges and sustained cash burn. Investors should weigh the bullish analyst targets against the company's current unprofitability and high valuation multiples.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
